Tala Achkar

Tala Achkar

Auto-generated profile, based on publicly available information

Tala Achkar

Hematology Department, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2017 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
TATala Achkar
Tala Achkar
ATAhmad Tarhini
Ahmad Tarhini
Patients with advanced melanoma have a compromised anti-tumor immune response leading to tumor immune tolerance and a tumor microenvironment conducive to disease progression. Immunotherapy that successfully overcomes this tumor-mediated immune suppression has made the greatest impact in the management of this disease over the past few years. This progress through immunotherapy builds upon earlier successes that interferon-α had in the treatment of melanoma in the adjuvant setting, as well as that of high-dose interleukin-2 in advanced melanoma. The development of immune checkpoint inhibitors has led to dramatic clinical activity in advanced melanoma. In particular, anti-CTLA4 and anti-PD1 monoclonal antibodies have taken us forward into the realm of longer survival and durable responses with the possibility of cure in a continuously increasing proportion of patients. Combination immunotherapeutic strategies and novel immunotherapeutic agents are being tested at an accelerated pace where the outlook for long-term survival benefits for the majority of patients appears brighter than ever.

1 May 2010 in Developmental Biology
Verified
Journal Article
Closed access
LJLoydie Jerome-Majewska
Loydie Jerome-Majewska
TATala Achkar
Tala Achkar
LLLi Luo
Li Luo
FLFloria Lupu
Floria Lupu
ELElizabeth Lacy
Elizabeth Lacy

20 December 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TATala Achkar
Tala Achkar
AAAnanth Arjunan
Ananth Arjunan
Hong WangHong Wang
Hong Wang
MSMelissa Saul
Melissa Saul
DDDiwakar Davar
Diwakar Davar
RPRahul A. Parikh
Rahul A. Parikh
High-dose interleukin-2 (HD IL-2) is used in the treatment of metastatic renal cell carcinoma (mRCC) and has an overall response rate (ORR) of 12–20% and a complete response rate (CR) of 8% in unselected populations with predominantly clear cell type renal cell carcinoma. Nearly 10–15% of patients with renal cell carcinoma exhibit sarcomatoid differentiation, a feature which correlates with a median overall survival (OS) of 9 months and overall poor prognosis. We report a single institution experience with 21 patients with mRCC with sarcomatoid features post-nephrectomy who were treated with HD IL-2. Twenty one patients with mRCC with sarcomatoid features post-nephrectomy who underwent therapy with HD IL-2 were identified at the University of Pittsburgh Medical Center from 2004 to 2016. Baseline patient characteristics, HD IL-2 cycles, time to progression, and subsequent therapies were evaluated. OS and progression-free survival (PFS) in the cohort were calculated using the Kaplan-Meier method. Disease characteristics were evaluated for significance using the Fischer′s exact test and Wilcoxon rank sum test. Patients were predominantly Caucasian males with a median age of 54 years. A majority, 86% of these patients, had metastatic disease at time of initial presentation, primarily with lung and lymph node involvement. The ORR and CR with HD IL-2 was 10% and 5%, respectively. Initial localized disease presentation is the only variable that was significantly associated with response to HD IL-2 (p = 0.0158). Number of HD IL-2 doses did not correlate with response with a mean of 16.5 and 15.0 total doses in responders and non-responders, respectively (p = 0.53). Median PFS with HD IL-2 was 7.9 months (95% CI, 5.0–21.3). Median OS was 30.5 months (95% CI 13.3–57.66). Within the subset of patients who had progression on IL-2, median OS was 19.4 months (95% CI, 13.3–35.3). In patients who received second-line therapy, median PFS was 7.9 months (95% CI 2.4–10.2). In patients with mRCC with sarcomatoid features, use of HD IL-2 was associated with a modest ORR and a higher survival compared to historical controls (patients with mRCC and sarcomatoid features). Thus, HD IL-2 may have a role in treating selected patients with mRCC with sarcomatoid features.

28 August 2017 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
AMAju Mathew
Aju Mathew
TATala Achkar
Tala Achkar
SAShira Abberbock
Shira Abberbock
GSGurprataap S. Sandhu
Gurprataap S. Sandhu
MJMini Elizabeth Jacob
Mini Elizabeth Jacob
ABAdam M. Brufsky
Adam M. Brufsky

24 December 2015 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TATala Achkar
Tala Achkar
JWJohn Wilson
John Wilson
JSJacqueline Simon
Jacqueline Simon
MRMargaret Rosenzweig
Margaret Rosenzweig
SPShannon Puhalla
Shannon Puhalla

Verified
Journal Article
Open access
PDF file
IKIyad Kobeissi
Iyad Kobeissi
IEIslam Eljilany
Islam Eljilany
TATala Achkar
Tala Achkar
WLWilliam LaFramboise
William LaFramboise
Lucas Santana dos SantosLucas Santana dos Santos
Lucas Santana dos Santos
ATAhmad Tarhini
Ahmad Tarhini
Despite the unprecedented advances in the treatment of melanoma with immunotherapy, there continues to be a major need for biomarkers of clinical benefits and immune resistance associated with immune checkpoint inhibitors; microRNA could play a vital role in these efforts. This study planned to identify differentially expressed miRNA molecules that may have prognostic value for clinical benefits. Patients with surgically operable regionally advanced melanoma were treated with neoadjuvant ipilimumab (10 mg/kg intravenously every 3 weeks × two doses) bracketing surgery. Tumor biospecimens were obtained at baseline and surgery, and microRNA (miRNA) expression profiling was performed on the tumor biopsies. We found that an expression profile consisting of a 4-miRNA signature was significantly associated with improved relapse-free survival (RFS). The signature consisted of biologically relevant molecules previously reported to have prognostic value in melanoma and other malignancies, including miR-34c, miR-711, miR-641, and miR-22. Functional annotation analysis of target genes for the 4-miRNA signature was significantly enriched for various cancer-related pathways, including cell proliferation regulation, apoptosis, the MAPK signaling pathway, and the positive regulation of T cell activation. Our results presented miRNAs as potential biomarkers that can guide the treatment of melanoma with immune checkpoint inhibitors. These findings warrant further investigation in relation to CTLA4 blockade and other immune checkpoint inhibitors. ClinicalTrials.gov NCT00972933.